Switzerland offers an outstanding framework for procuring capital. The Swiss stock exchange is Europe’s leading exchange for life sciences companies, representing around 40% of the European life sciences market capitalization across Europe’s major stock exchanges. The economic and scientific environment boasts the presence of successful international chemical and pharmaceutical companies, such as Novartis and Roche, as well as innovative firms from the medical technology, biotechnology, and nanotechnology sectors, making it highly suitable for strategic partnerships, licensing, or patent sales. Modern infrastructure, high quality of life, and access to excellently trained employees supplement the extremely positive conditions for a strong and future-oriented biotechnology industry in Switzerland.
